You searched for "macular"
Aflibercept (AF) for age-related macular degeneration (ARMD): four-year outcomes of a ‘’treat-and-extend’ (T&E) regimen with exit-strategy
This is a retrospective observational study of 82 patients, between 2014 to 2016 from Switzerland of treatment-naive patients with nARMD, treated with AF, with specific T&E protocol without a loading phase and predefined exit criteria and patients were observed three...
The evolution and visual prognosis of glial proliferation of different grades after macular hole surgery
3 April 2024
| Sofia Rokerya
|
EYE - Neuro-ophthalmology
This retrospective research study aimed to investigate the evolution of glial proliferation of varying grades after successful idiopathic macular hole repair and its effects on foveal microstructure and best-corrected visual acuity (BCVA). Two-hundred and two eyes were enrolled in this...
Outcomes at 100 weeks from the LEAVO study of intravitreal anti-VEGF therapies for macular oedema secondary to central retinal vein occlusion
23 May 2019
| Rod McNeil
Royal College of Ophthalmologists Annual Congress 2019, Glasgow - First presented and discussed on Monday 20 May 2019, with a further presentation of results during Retina Subspecialty Day on Thursday 23 May 2019. Among patients with macular oedema secondary to...
SpaMedica announces partnership with Macular Society
SpaMedica, one of the UK’s leading independent providers of NHS eye care services, is proud to announce a new partnership with the Macular Society, set to launch this month. The collaboration will help to fund ground-breaking research and vital support...Macular Society chief executive, Cathy Yelf, announces retirement
After nearly a decade of dedicated service as chief executive of leading sight loss charity the Macular Society, Cathy Yelf has announced her decision to retire in 2024.Topcon Healthcare Lecture: Use of Macular Ganglion Cell Layer in Neuroophthalmology
19 March 2025
Speaker: Shveta BansalConsultant Ophthalmologist, Lancashire Eye Centre Shveta Bansal specialises in Neuroophthalmology and Ocular Motility. She offers specialist units in Neuro and Motility to the region and is a core partner in the Trust Neurosciences MDT. Her training included fellowships...
RCOphth (The Royal College of Ophthalmologists) Management of Diabetic macular oedema: state-of-the-art
17 April 2024
Talks will include: 1) OCT biomarkers in DMO - what adds value in clinical-decision making? - Christiana Dinah, Consultant Ophthalmologist and medical retina specialist, London 2) Debate: When should you switch treatment in DMO? versus late - Deepali Varma, Consultant...
2024 Howard Foundation Lecture by Professor John Nolan
13 May 2024
18:00pm - 20:15pm
Intravitreal bevacizumab vs. triamcinolone in patients with DMO at the time of cataract surgery
1 October 2016
| Anjali Gupta
|
EYE - Vitreo-Retinal
This prospective, single masked randomised control trial (RCT) compared visual and anatomical outcomes when either intravitreal bevacizumab (BVB) or triamcinolone (TA) was administered at the time of cataract surgery and at subsequent review, if required, in patients with diabetic macula...
A paradigm shift in the way we approach cataract surgery
Cataract surgery is the most common elective surgical procedure in the UK [1], with in the region of 350,000 cases being conducted each year. With an ageing population, this figure will only continue to rise over time. Cataract surgery is...Macula re-attachment following intravitreal ranibizumab in rhegmatogenous retinal detachment
Ranibizumab (Lucentis) is a vascular endothelial growth factor inhibitor (anti-VEGF) used for treatment of choroidal neovascular membrane [1]. We report a case where macula off inferior rhegmatogenous retinal detachment was misdiagnosed as wet age-related macular degeneration (AMD) and three intravitreal...
